OakChart

Atossa Therapeutics Inc

ATOSHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

2.03-0.11 (-5.14%)
2026-11-11 22:31 CET
Market cap
21.36 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-34.66 USD m
Free cash flow, TTM
-35.29 USD m
EPS diluted, TTM
-3.90
P/E
-
Compare

Price

ATOS against its 20, 50 and 200-day averages
2050200beat
2.004.006.008.0010.00710K1.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ATOSclose 2.0320-day 2.3750-day 2.35200-day 3.652.03

86.3% under the 52-week high of 14.85 on 11 Dec 2025. 52-week low 1.70 on 25 Jun 2026. Last 15 sessions, 43.9% high to low

Volume 0.57× normal · the line is the 50-bar volume average

Profile

ATOS
52-week range, 3% of the way up
1.7014.85

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Employees14
IPONov 08, 2012
Beta1.37
ATR, 14d0.21
Rel volume0.57
Short float5.36%
Insider own1.52%
Inst own13.53%

Snapshot

6 groups

Valuation

Index-
Market Cap20.26M
Enterprise Value-0.42M
Income-34.66M
Sales0.00M
Book/sh2.18
Cash/sh2.07
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees14
IPONov 08, 2012

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.93
P/C0.98
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio5.35
Current Ratio5.35
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.90
EPS next Y-2.78
EPS next Q-0.86
EPS this Y7.26%
EPS next Y25.71%
EPS next 5Y-
EPS past 3/5Y-8.13% 32.87%
Sales past 3/5Y- -
EPS Y/Y TTM-10.80%
Sales Y/Y TTM-
EPS Q/Q44.09%
Sales Q/Q-
EarningsNov 10 BMO
EPS/Sales Surpr.34.63% -

Ownership

Insider Own1.52%
Insider Trans0.00%
Inst Own13.53%
Inst Trans1.11%
ROA-82.06%
ROE-96.90%
ROIC-159.41%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-14.16%
SMA50-13.66%
SMA200-44.42%
Trades-

Technical

Shs Outstand9.98M
Shs Float9.83M
Short Float5.36%
Short Ratio7.41
Short Interest0.53M
52W High14.85 -86.33%
52W Low1.70 19.41%
Volatility8.90% 10.21%
ATR (14)0.21
RSI (14)39.06
Beta1.37
Rel Volume0.57
Avg Volume71.06K
Volume40,392

Performance

Perf Week-4.25%
Perf Month-20.70%
Perf Quarter-20.70%
Perf Half Y-60.66%
Perf YTD-77.06%
Perf Year-83.65%
Perf 3Y-78.69%
Perf 5Y-94.73%
Perf 10Y-99.36%
Recom1.00
Target Price17.00
Prev Close2.14
Price2.03
Change %-5.14%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Jul 07, 2026InitiatedRRodman & RenshawBuy$12+491.1%
Jan 26, 2018InitiatedMMaxim GroupBuy$2-1.5%

Peers

Mkt cap
TickerCompanyMkt cap
LONALeonaBio Inc36.56M
OLMAOlema Pharmaceuticals Inc703.48M
CELCCelcuity Inc3.16B
BCTXBriaCell Therapeutics Corp31.34M
PBYIPuma Biotechnology Inc417.72M
GLSIGreenwich LifeSciences Inc236.17M
CNTXContext Therapeutics Inc19.85M
ANIXAnixa Biosciences Inc96.65M
VERUVeru Inc36.49M
ENSCEnsysce Biosciences Inc7.00M

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 200
  • Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update (PR Newswire)
  • Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today (PR Newswire) -12.03%
  • Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value (PR Newswire)
  • Atossa plans shareholder stake in potential PRV proceeds (Pharmaceutical Technology)
  • Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher (PR Newswire)
  • Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging (PR Newswire) -5.96%
  • Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update (PR Newswire)
  • Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer (PR Newswire)
  • Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers (PR Newswire)
  • Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds (PR Newswire)
  • Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds (PR Newswire) -41.25%
  • Atossa Therapeutics highlights Endoxifen progress as potential Breast Cancer treatment (Proactive)
  • Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial (PR Newswire)
  • Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.560-0.857-0.5600.000.003
2026Q22026-08-07-0.950-1.025-0.9530.000.002
2026Q12026-05-08-1.110-0.990-1.1120.000.003
2025Q42026-03-25-1.190-1.138-1.2700.000.004
2025Q32025-11-12-1.050-0.975-1.0090.000.004
2025Q22025-08-12-1.050-0.863-0.9780.000.004
2025Q12025-05-13-0.750-0.851-0.7800.000.003
2024Q42025-03-25-0.600-0.950-0.7520.000.003
2024Q32024-11-12-0.900-0.900-0.8620.000.004
2024Q22024-08-12-0.750-0.900-0.7220.000.004
2024Q12024-05-13-0.750-1.001-0.7040.000.003
2023Q42024-04-01-0.900-0.900-0.9280.000.004
2023Q32023-11-13-0.750-1.001-0.7430.000.003
2023Q22023-08-14-1.200-0.900-1.1650.000.002
2023Q12023-05-15-0.750-0.900-0.7440.000.002
2022Q42023-03-22-0.900-0.975-0.8870.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-30.450--30.434--
2020FY-29.550-16.725-29.6200.000.00
2021FY-2.700-2.775-2.6430.000.00
2022FY-3.150-3.300-3.1940.000.00
2023FY-3.600-3.600-3.5800.000.00
2024FY-3.000-3.250-3.0400.000.00
2025FY-4.040-3.908-4.0400.000.00
2026FY--3.747--0.00
2027FY--2.783--0.00
2028FY-2.715--118.73
2029FY-11.950--337.31
2030FY-18.850--517.12

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-102000.000.000.00
2026Q4S2026-09-292000.000.000.00
2026Q4S2026-08-071000.000.000.00
2026Q4S2026-07-171000.000.000.00
2026Q4S2026-06-122000.000.000.00
2026Q4S2026-05-133000.000.000.00
2026Q4S2026-05-082000.000.000.00
2026Q4S2026-04-132000.000.000.00
2026Q4S2026-04-083000.000.000.00
2026Q4S2026-03-262000.000.000.00
2026Q4S2025-11-123000.000.000.00
2026Q4S2025-11-112000.000.000.00
2026Q4S2025-11-102000.000.000.00
2026Q4R2026-11-10200-0.91-1.08-0.73

Estimate history

EPS, annual-163.8-82.56-30.434-29.62-2.643-3.194-3.58-3.04-4.038-3.8997
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.862-0.752-0.78-0.978-1.009-1.27-1.112-0.953-0.564
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.1770.390.6093.178.4428.4428.3548.6118.6119.979
Period201720182019202020212022202320242025MRQ
Shares, quarterly8.3548.6118.6118.6118.6118.6118.6119.9799.979
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.020.020.020.020.010.020.050.050.04
Gross Profit-0.02-0.02-0.02-0.02-0.01-0.02-0.05-0.05-0.04
Selling, General and Administrative Excl. Other35.8837.1227.6031.3527.6820.5014.5617.2111.39
Research and Development19.2121.1814.1217.3315.089.216.616.654.21
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-35.90-37.14-27.62-31.38-27.69-20.52-14.61-17.27-11.43
Interest Expense0.000.000.000.000.000.000.00-0.00
Unusual Expense0.000.001.712.990.000.002.33-0.00
Net Income Before Taxes-34.66-34.77-25.50-30.09-26.96-20.61-17.83-17.24-11.40
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-34.66-34.77-25.50-30.09-26.96-20.61-17.83-17.24-11.40
Net Income From Continuing Operations-34.66-34.77-25.50-30.09-26.96-20.61-17.83-17.24-11.40
Net Income-34.66-34.77-25.50-30.09-26.96-20.61-22.33-17.24-22.88
EPS (Recurring)-3.47-4.04-2.90-3.33-3.19-2.64-27.45-30.43-82.56
EPS (Basic, Before Extraordinaries)-3.90-4.04-3.04-3.58-3.19-2.64-29.62-30.43-82.56
EPS (Diluted)-3.90-4.04-3.04-3.58-3.19-2.64-29.62-30.43-82.56
EBITDA-35.88-37.12-27.60-31.35-27.68-20.50-14.56-17.21-11.39
Non-Operating Income (Expense)1.242.373.834.270.73-0.09-0.890.030.03
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.592.652.294.626.795.273.027.101.05
Shares Outstanding9.988.618.618.358.448.443.170.610.39
Market Capitalization21.3621.36121.95110.2766.92202.6045.1714.345.96

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Selling, General and Administrative Excl. Other5.898.699.8711.439.259.047.417.15
Research and Development3.384.904.786.165.375.504.163.40
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-5.90-8.69-9.87-11.44-9.25-9.04-7.41-7.15
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-5.64-8.49-9.59-10.94-8.69-8.42-6.72-6.35
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-5.64-8.49-9.59-10.94-8.69-8.42-6.72-6.35
Net Income From Continuing Operations-5.64-8.49-9.59-10.94-8.69-8.42-6.72-6.35
Net Income-5.64-8.49-9.59-10.94-8.69-8.42-6.72-6.35
EPS (Recurring)-0.56-0.95-1.11-1.27-1.01-0.98-0.78-0.75
EPS (Basic, Before Extraordinaries)-0.56-0.95-1.11-1.27-1.01-0.98-0.78-0.75
EPS (Diluted)-0.56-0.95-1.11-1.27-1.01-0.98-0.78-0.75
EBITDA-5.89-8.69-9.87-11.43-9.25-9.04-7.41-7.15
Non-Operating Income (Expense)0.260.200.280.500.560.620.700.80
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.550.810.720.500.780.800.560.77
Shares Outstanding9.989.988.618.618.618.618.618.61
Market Capitalization21.3619.2545.3076.21111.99107.2186.92121.95

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments41.4171.1988.57111.00136.4939.6612.6910.497.27
Short Term Receivables0.000.000.000.741.070.630.740.520.36
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets4.213.263.656.453.682.470.890.540.27
Total Current Assets45.6274.4692.22118.20141.2442.7714.3211.557.90
Net Property, Plant & Equipment0.000.000.000.000.020.040.080.050.01
Total Investments and Advances0.000.001.714.700.000.000.000.000.00
Intangible Assets----0.000.010.070.100.08
Deferred Tax Assets---0.000.000.000.01--
Other Assets1.991.992.320.640.000.020.020.020.18
Total Assets47.6176.4496.25123.53141.2642.8414.5011.728.16
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.020.040.000.00
Accounts Payable4.290.680.812.961.721.590.290.350.33
Other Current Liabilities3.964.294.432.601.4114.060.992.560.89
Total Current Liabilities8.264.975.245.573.1315.671.322.921.23
Long Term Debt0.000.000.000.000.000.000.010.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities---0.000.000.000.01--
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities8.264.975.245.573.1315.681.342.921.23
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.580.580.620.672.380.00
Common Equity39.3571.4891.02117.38137.5526.5512.496.436.94
Total Shareholders Equity39.3571.4891.02117.96138.1427.1713.168.816.94
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity39.3571.4891.02117.96138.1427.1713.168.816.94
Total Liabilities & Stockholders Equity47.6176.4496.25123.53141.2642.8414.5011.728.16
Book Value Per Share4.578.3010.9013.9116.298.3720.5116.4939.25
Tangible Book Value Per Share4.578.3010.9013.9116.298.3720.4016.2338.82
Full-Time Employees1415121188647
Price to Book Ratio0.981.711.130.541.471.701.150.931.44
Return on Assets-56.06-29.54-27.38-20.36-22.38-62.18-131.50-114.71-131.98
Return on Equity-62.74-31.39-28.80-21.05-24.93-88.42-157.00-144.88-161.87
Return on Invested Capital-88.35-35.68-33.06-22.85-14.92-65.62-130.93-129.53-117.06
Quick Ratio5.5314.9917.6121.2345.182.7310.833.966.45
Current Ratio5.5314.9917.6121.2345.182.7310.833.966.45

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-34.66-34.77-25.50-30.09-26.96-20.61-17.83-17.24-11.40
Depreciation0.020.020.020.020.010.020.050.050.04
Other Funds (Non Cash)2.592.654.017.616.795.276.328.852.46
Funds from Operations-32.05-32.11-21.48-22.46-20.16-15.32-11.46-8.34-8.90
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-3.232.350.451.52-0.60-1.16-0.11-0.79-0.06
Cash from Operating Activities-35.28-29.76-21.03-20.94-20.76-16.47-11.57-9.13-8.96
Capital Expenditures-0.01-0.02-0.02-0.01-0.03-0.01-0.01-0.01-0.11
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.00-4.700.000.000.000.00
Purchase of Investments0.000.000.000.00-4.700.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.01-0.02-0.02-0.01-4.73-0.01-0.01-0.01-0.11
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock4.020.003.67-1.480.00113.8838.5711.3412.29
Repurchase of Common Pref Stock0.000.000.00-1.480.000.000.000.000.00
Sale of Common Pref Stock4.020.003.670.000.00113.8838.5711.3412.29
Proceedsfrom Stock Options0.020.000.000.000.0069.6738.570.0012.29
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00-0.57-0.010.000.00
Other Financing Activities Uses0.000.000.000.000.00-0.57-0.010.000.00
Cash from Financing Activities4.020.003.67-1.480.00113.3038.5511.3412.29
Net Change in Cash-31.27-29.79-17.38-22.43-25.4996.8226.972.203.22
Free Cash Flow-35.29-29.79-21.05-20.95-20.79-16.48-11.58-9.14-9.07
Preferred Dividends (Cash Flow)-0.000.000.000.000.00---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments20.6826.2031.8341.4151.9557.97
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets4.504.814.844.213.724.55
Total Current Assets25.1831.0136.6745.6255.6862.52
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Other Assets1.271.271.271.992.332.00
Total Assets26.4532.2837.9447.6158.0164.52
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable1.501.982.574.293.542.01
Other Current Liabilities3.213.484.893.964.694.81
Total Current Liabilities4.715.457.468.268.226.82
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities4.715.457.468.268.226.82
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity21.7426.8330.4939.3549.7957.70
Total Shareholders Equity21.7426.8330.4939.3549.7957.70
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity21.7426.8330.4939.3549.7957.70
Total Liabilities & Stockholders Equity26.4532.2837.9447.6158.0164.52
Book Value Per Share2.182.693.544.575.786.70
Tangible Book Value Per Share2.182.693.544.575.786.70
Full-Time Employees---14--
Price to Book Ratio0.980.551.151.942.251.86
Return on Assets-82.06-77.91-69.26-56.06-43.90-38.20
Return on Equity-96.90-89.23-78.58-62.74-48.89-41.66
Return on Invested Capital-25.93-31.65-31.45-27.79-17.46-14.60
Quick Ratio5.355.694.925.536.779.17
Current Ratio5.355.694.925.536.779.17

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-5.64-8.49-9.59-10.94-8.69-8.42
Depreciation0.000.000.000.000.000.00
Other Funds (Non Cash)0.550.810.720.500.780.80
Funds from Operations-5.09-7.67-8.86-10.43-7.90-7.62
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.43-1.97-0.72-0.111.900.36
Cash from Operating Activities-5.52-9.64-9.58-10.54-6.00-7.26
Capital Expenditures0.000.000.00-0.01-0.010.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.00-0.01-0.010.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.004.020.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.004.020.000.000.000.00
Proceedsfrom Stock Options0.000.020.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.004.020.000.000.000.00
Net Change in Cash-5.52-5.62-9.58-10.55-6.01-7.26
Free Cash Flow-5.52-9.64-9.58-10.55-6.01-7.26

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.36%0.5M9.8M71.14K
2026-10-156.95%0.7M9.8M68.55K
2026-09-308.02%0.8M9.8M75.65K
2026-09-157.75%0.8M9.8M116.76K
2026-08-317.69%0.8M9.8M153.95K
2026-08-148.09%0.8M9.8M152.56K
2026-07-317.74%0.8M9.8M153.70K
2026-07-157.90%0.8M9.8M154.09K
2026-06-307.18%0.7M9.8M135.53K
2026-06-155.44%0.5M9.8M95.22K
2026-05-294.74%0.4M8.5M65.39K
2026-05-154.03%0.3M8.5M71.13K
2026-04-303.96%0.3M8.5M112.14K
2026-04-154.13%0.4M8.5M137.96K
2026-03-313.82%0.3M8.6M140.83K
2026-03-133.73%0.3M8.6M144.47K
2026-02-274.21%0.4M8.6M140.81K
2026-02-134.76%0.4M8.6M134.09K
2026-01-303.65%0.3M8.6M88.95K
2026-01-152.81%0.2M8.6M64.37K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.000.651.650.0014.0420.000.000.936-0.0360.000
call2.000.001.000.608.9417.000.000.717-0.0440.001
call3.000.001.000.153.64718.000.000.344-0.0240.001
call4.000.001.000.004.7790.000.000.295-0.0300.001
call5.000.000.050.053.4093.000.000.108-0.0110.001
call6.000.001.000.014.3041.000.000.100-0.0140.001
put1.000.001.000.3315.9361.000.00-0.064-0.0350.000
put2.000.000.700.055.93151.000.00-0.288-0.0420.001
put3.000.451.400.955.5421.000.00-0.656-0.0240.001
put4.001.352.350.006.3430.000.00-0.705-0.0290.001
put5.002.403.400.007.5760.000.00-0.891-0.0120.001
put6.003.404.403.228.2100.000.00-0.900-0.0130.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-KCurrent report2026-11-10SEC
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-098-KCurrent report2026-10-08SEC
2026-09-298-KCurrent report2026-09-29SEC
2026-09-188-KCurrent report2026-09-18SEC
2026-08-078-KCurrent report2026-08-07SEC
2026-08-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-06-12424B5SEC
2026-06-118-KCurrent report2026-06-10SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-088-KCurrent report2026-05-08SEC
2026-05-0810-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-088-KCurrent report2026-05-07SEC
2026-04-168-KCurrent report2026-04-13SEC
2026-03-314Statement of changes in beneficial ownership of securities2026-03-27SEC
2026-03-304Statement of changes in beneficial ownership of securities2026-03-26SEC
2026-03-30ARSAnnual report to security holders. 2025-12-31SEC
2026-03-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-03-30SEC
2026-03-2510-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-258-KCurrent report2026-03-25SEC
2026-03-20PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-03-20SEC
2026-02-208-KCurrent report2026-02-19SEC
2026-02-20424B5SEC
2026-02-20424B3SEC
2026-02-178-KCurrent report2026-02-17SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC3.63%
AMERIPRISE FINANCIAL INC2.59%
BlackRock, Inc.1.65%
RENAISSANCE TECHNOLOGIES LLC1.32%
GEODE CAPITAL MANAGEMENT, LLC0.96%
JANE STREET GROUP, LLC0.57%
VANGUARD FIDUCIARY TRUST CO0.53%
MILLENNIUM MANAGEMENT LLC0.47%
STATE STREET CORP0.40%
UBS Group AG0.31%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.57%
Columbia Small Cap Value Discovery Fund2.02%
VANGUARD EXTENDED MARKET INDEX FUND0.99%
Fidelity Extended Market Index Fund0.45%
Columbia Variable Portfolio - Small Cap Value Discovery Fund0.36%
iShares Micro-Cap ETF0.29%
Fidelity Total Market Index Fund0.14%
Fidelity Series Total Market Index Fund0.13%
VANGUARD BALANCED INDEX FUND0.07%
Fidelity Nasdaq Composite Index Fund0.05%

OakChart. ATOS. Cached 15 minutes.

Some panels did not load: insider.